Actively Recruiting
Phase 1 Study of CD19 CAR-T Cells with IL-7 and CCL19 Combined with Tislelizumab for Treating Relapsed or Refractory Diffuse Large B-cell Lymphoma
Led by Ningbo No. 1 Hospital · Updated on 2022-12-21
24
Participants Needed
2
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining CD19-719 CAR-T cells with Tislelizumab in adults with relapsed or refractory diffuse large B-cell lymphoma DLBCL. This Phase 1b clinical trial focuses on patients who have not responded to previous treatments or have relapsed, aiming to better understand the treatments impact on this condition. Participants will receive an infusion of CD19-719 CAR-T cells at a dose of 2106 cells per kilogram. Before this infusion, they undergo chemotherapy with fludarabine and cyclophosphamide. Starting 31 days after the CAR-T cell infusion, participants receive Tislelizumab 200 mg every 21 days for six cycles. This combined treatment is carefully monitored throughout the study. During the trial, participants will undergo clinical evaluations including physical exams, blood tests, biochemical tests, and imaging before CAR-T cell infusion. Peripheral blood lymphocytes are collected to prepare CAR-T cells. Disease status and any side effects will be regularly assessed, and participants will report any medications and adverse events. The study will measure safety by monitoring adverse events up to 28 days after treatment and evaluate treatment response within three months. Longer-term outcomes like progression-free survival and overall survival will be observed up to 24 months.
CONDITIONS
Brief Title
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
Research Team
L
Lixia Sheng, doctor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here